Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor

Chang, Ying‐Jun; Zhao, Xiang-Yu; Huo, Ming-Rui

doi:10.1016/j.trim.2009.05.005

Cited by 23 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treating healthy donor with G-CSF significantly increased the percentages of IL-4-positive cells in BM-naive CD4+ and CD8+ T-cell subsets. 32 G-CSF can induce BM T-cell hyporesponsiveness and polarize T cells from Th1 to Th2 phenotype. 32 All lymphocyte subsets exhibited 26-to 46-fold higher cell counts and the CD4/CD8 ratio was also significantly higher in G-PB than in G-BM.…”

Section: Effect Of Pre-collection Of G-csf Administration On the Progmentioning

confidence: 99%

“…32 G-CSF can induce BM T-cell hyporesponsiveness and polarize T cells from Th1 to Th2 phenotype. 32 All lymphocyte subsets exhibited 26-to 46-fold higher cell counts and the CD4/CD8 ratio was also significantly higher in G-PB than in G-BM. 33 G-CSF treatment on BMs decreased the quantities of IFN-γ secretion dramatically (P = 0.007) and IL-4 moderately (P = 0.027), leading to higher ratios of IL-4/IFN-γ (P = 0.004).…”

Section: Effect Of Pre-collection Of G-csf Administration On the Progmentioning

confidence: 99%

“…40 Recently, a phase III randomized multicenter trial of matched sibling G-CSF-primed PB versus G-BM was completed by the Canadian Bone Marrow Transplant Group. 41 Between 2007 and 2012, 230 donor-recipients pairs aged 16-65 years received myeloablative conditioning (Bu/Cy and Cy/TBI) with a combination of cyclosporine and methotrexate as GvHD prophylaxis.…”

Section: G-bm In Related-donor Allogeneic Hsc Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

Deotare

Aldawsari

Couban

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Effect Of Pre-collection Of G-csf Administration On the Progmentioning

confidence: 99%

Section: Effect Of Pre-collection Of G-csf Administration On the Progmentioning

confidence: 99%

Section: G-bm In Related-donor Allogeneic Hsc Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

Deotare

Aldawsari

Couban

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The expression of adhesion molecules involved in GVHD pathogenesis (by modulating T-cell migration and homing) decreases. 59,66 The numbers of immunosuppressive or immunomodulatory MSCs, which are not found in the PB progenitor cell collections, and improve GVHD in experimental and clinical models, increase. 59,67,68 The nucleated cells and monocytes are many times fewer in GBM than in GPB.…”

Section: Introductionmentioning

confidence: 99%

G-CSF-primed BM for allogeneic SCT: revisited

Pessach

Resnick²,

Shimoni

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

G-SCF-mobilized PBSC (GPB) grafts have a higher cell dose and somewhat more committed progenitor cells than steady-state BM (SBM), resulting in faster engraftment and faster immunological reconstitution. On the other hand, transplant related mortality (TRM), disease-free survival (DFS) and overall survival (OS) are similar both for PB and for BM. In contrast to SBM, G-CSF-primed BM (GBM) grafts stimulate HSC proliferation, increasing cell dose and thus resulting in faster engraftment because of higher cell dose infused, or because of treatment with G-CSF. Furthermore, GBM may induce tolerance and functional modulations in donor hematopoiesis and immunity, further reducing GVHD incidence, which is already lower with SBM compared with GPB grafts. Overall, a growing body of clinical evidence suggests that GBM transplants may share the advantages of GPB transplantations, without the associated increased risk of GVHD, and might be an attractive graft source for allogeneic SCTs.

show abstract

“…Furthermore, the use of G-CSF-mobilized DLI combined with short-term immunosuppressants for GVHD prophylaxis may play a role in reducing cGVHD occurrence [25]. The effect of in vivo G-CSF application on T-cell hyporesponsiveness has been extensively explored [25][26][27][28]. In addition, our previous data also indicate that in vivo G-CSF application could induce a decrease in Th17 cells [8].…”

mentioning

confidence: 99%

Donor Th17 cells and IL‐21 may contribute to the development of chronic graft‐versus‐host disease after allogeneic transplantation

Zhao

et al. 2013

Eur J Immunol

Self Cite

View full text Add to dashboard Cite

Keywords: Chronic GVHD r HSCT r IL-21 r Th17Additional supporting information may be found in the online version of this article at the publisher's web-site IntroductionAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered an effective treatment method for hematological malignancies, but graft-versus-host disease (GVHD) is a potentially lethal complication after allo-HSCT. Chronic GVHD (cGVHD) is not only a major cause of nonrelapse mortality but also induces substantial morbidity, which can severely affect the quality of life [1,2]. Despite improvements in the practice of allo-HSCT over the Correspondence: Prof. Xiao-Jun Huang e-mail: xjhrm@medmail.com.cn last 30 years, there has been little change in the incidence, morbidity, and mortality of cGVHD. One of the difficulties in combating cGVHD is the poor understanding of its pathogenesis [3].Chronic GVHD differs from acute GVHD (aGVHD) in many aspects. cGVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases, such as systemic lupus erythematosus, Sjögren's syndrome, lichen planus, and scleroderma. However, in contrast to aGVHD, it is unclear how autoimmune responses develop in cGVHD [3,4].IL-17-producing CD4 + T lymphocytes, named Th17 cells, play a crucial role in triggering inflammation and tissue injury in several autoimmune diseases [5]. Increasingly, the Th17 differentiation pathway has been shown to play important roles in aGVHD [6,7]. We previously demonstrated that IL-17-producing C 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu Eur. J. Immunol. 2013. 43: 838-850 Clinical immunology 839T cells contribute to aGVHD after allogeneic blood marrow transplantation [8]. However, the role of Th17 cells in cGVHD is controversial [7,[9][10][11]. Using the B10.D23→BALB/c cGVHD model, Nishimori et al. [9] show that cGVHD is significantly ameliorated in recipients of IL-17 −/− B10. D2 donor T cells compared with recipients of wild-type T cells, suggesting that Th17 cells contribute to cGVHD in this model. However, the (B6→BALB/c)→B6 Rag cGVHD model of Chen et al. [10] shows that cGVHD is not significantly ameliorated in recipients transplanted with IL-17 −/− B6 donor T cells, suggesting that IL-17 is not required for autoimmune-mediated pathologic damage during cGVHD. Furthermore, recent clinical data have also demonstrated contradictory roles for IL-17 as a central mediator of cGVHD pathology [7,11]. The work of Dander et al. [7] demonstrates an increased Th17-cell population in patients with cGVHD in addition to an inflammatory process. However, Ratajczak et al. [11] found that although skin-infiltrating Th17 cells can be identified by immunohistochemistry through IL-17A expression, the Th17/Treg-cell ratio is significantly lower than that observed in non-GVHD controls, which argues against a pathogenic role for the Th17 subset. Therefore, the role of Th17 cells in the pathogenesis of cGVHD must be further explored. Moreover, a recent study has shown that IL-21, one of the m...

show abstract

Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor

Cited by 23 publications

References 27 publications

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

G-CSF-primed BM for allogeneic SCT: revisited

Donor Th17 cells and IL‐21 may contribute to the development of chronic graft‐versus‐host disease after allogeneic transplantation

Contact Info

Product

Resources

About